Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP3 | P15309 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18920447 | 1.00 | ACP3 (0.47) | ACP3ALDH1A1GAAAOC3OPRM1 | |
| SCHEMBL18946106 | 1.00 | ACP3 (0.47) | ACP3ALDH1A1GAAAOC3OPRM1 | |
| SCHEMBL15565601 | 0.86 | ACP3 (0.44) | ACP3ALDH1A1GAAAOC3OPRM1 | |
| SCHEMBL888839 | 0.83 | ACP3 (0.41) | ACP3ALDH1A1GAAAOC3OPRM1 | |
| SCHEMBL10120515 | 0.81 | ACP3 (0.41) | ACP3ALDH1A1GAAAOC3OPRM1 | |
| SCHEMBL755740 | 0.81 | MEN1 (0.48) | OPRM1 | |
| SCHEMBL4218060 | 0.81 | ALDH1A1 (0.44) | ALDH1A1GAAPARP1 | |
| SCHEMBL755746 | 0.81 | ALDH1A1 (0.50) | ACP3ALDH1A1GAAAOC3 | |
| SCHEMBL10540988 | 0.81 | ALDH1A1 (0.51) | ALDH1A1GAA | |
| SCHEMBL222001 | 0.81 | ALDH1A1 (0.51) | ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108349965-B | 1,3, 4-thiadiazole compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2021-10-26 | — | — | CN | disclosed |
| EP-3383872-B1 | 1,3,4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | CANCER RESEARCH TECH LTD (GB) | 2020-05-20 | — | — | EP | disclosed |
| EP-3383872-B1 | 1,3,4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | CANCER RESEARCH TECH LTD (GB) | 2020-05-20 | — | — | EP | disclosed |
| EP-3383872-A1 | 1,3,4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | Astrazeneca AB (SE) | 2018-10-10 | — | — | EP | disclosed |
| US-10040789-B2 | 1,3,4-thiadiazole compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2018-08-07 | — | — | US | disclosed |
| US-20170355689-A1 | HEPATITIS C VIRUS INHIBITOR | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170333429-A1 | 1,3,4-Thiadiazole Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2017-11-23 | — | — | US | disclosed |
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-09 | — | — | US | disclosed |
| US-9776981-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-03 | — | — | US | disclosed |
| US-9758487-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-12 | — | — | US | disclosed |
| US-8143414-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110294819-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-01 | — | — | US | disclosed |
| US-20110286961-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-11-24 | — | — | US | disclosed |
| US-20110281910-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-11-17 | — | — | US | disclosed |
| US-20110274648-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-11-10 | — | — | US | disclosed |
| US-20110269956-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-11-03 | — | — | US | disclosed |
| US-20110237636-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-09-29 | — | — | US | disclosed |
| US-20110195044-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-08-11 | — | — | US | disclosed |
| US-20110130433-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-06-02 | — | — | US | disclosed |
| US-20110098327-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237636-A1 | Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | ACP3 2873/4885ALDH1A1 2120/4885GAA 327/4885 |
| US-20170355689-A1 | HEPATITIS C VIRUS INHIBITOR | HAVCR2, LIPC, PYGL | ACP3 1110/4885ALDH1A1 1107/4885GAA 226/4885 |
| US-20110294819-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, GTF3C1 | ACP3 2472/4885ALDH1A1 3778/4885GAA 777/4885 |
| US-20110286961-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | ACP3 956/4885ALDH1A1 1144/4885GAA 223/4885 |
| US-20110281910-A1 | Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | ACP3 2627/4885ALDH1A1 2265/4885GAA 354/4885 |
| US-20170333429-A1 | 1,3,4-Thiadiazole Compounds and Their Use in Treating Cancer | GLS2, GLS, GLRX3 | ACP3 2218/4885ALDH1A1 290/4885GAA 886/4885 |
| US-20110195044-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | ACP3 956/4885ALDH1A1 1144/4885GAA 223/4885 |
| US-10040789-B2 | 1,3,4-thiadiazole compounds and their use in treating cancer | GLS2, GLS, GLRX3 | ACP3 2218/4885ALDH1A1 290/4885GAA 886/4885 |
| US-20110269956-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, MAVS | ACP3 1257/4885ALDH1A1 1627/4885GAA 1070/4885 |
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | ACP3 956/4885ALDH1A1 1144/4885GAA 223/4885 |
| US-20110130433-A1 | Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | ACP3 2873/4885ALDH1A1 2120/4885GAA 327/4885 |
| US-20110098327-A1 | Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | ACP3 2546/4885ALDH1A1 2177/4885GAA 307/4885 |
| US-20110274648-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | ACP3 956/4885ALDH1A1 1144/4885GAA 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.